Cite
HARVARD Citation
Teramachi, J. et al. (2018). Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. British journal of haematology. pp. 581-585. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Teramachi, J. et al. (2018). Pim‐2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma. British journal of haematology. pp. 581-585. [Online].